Table 2 Cost-utility ratios of providing RSV immunoprophylaxis to infants by risk group and by annual hospitalizations in children aged 0–2 years old (a)
Risk Group | Annual hospitalizations in children aged 0–2 years | ||
|---|---|---|---|
2700 | 2945 | 3200 | |
Cost per DALY including asthma | Cost per DALY including asthma | Cost per DALY including asthma | |
CHD | $223,687 | $218,968 | $214,347 |
CLD | $303,658 | $287,057 | $268,242 |
<29 | $246,594 | $226,900 | $208,765 |
29–32 | $369,551 | $347,593 | $327,141 |
33–36 | $1,211,273 | $1,149,584 | $1,092,860 |
No risk | $3,217,414 | $3,023,294 | $2,849,644 |